Epirubicin in non-oat cell lung cancer--response rates and the importance of immunopathology: a Northern California Oncology Group Study

Cancer Treat Rep. 1986 Jun;70(6):805-6.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use*
  • Epirubicin
  • Female
  • Heart Diseases / chemically induced
  • Humans
  • Immunoenzyme Techniques
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Staining and Labeling
  • Statistics as Topic
  • Stereoisomerism

Substances

  • Epirubicin
  • Doxorubicin